IRRAS.ST Stock Analysis
IR
Uncovered
Irras AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Irras AB engages in the development, design, and commercialization of solutions for the treatment of brain pathologies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-11-22. The company offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company’s shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.